Platelet Inhibition, Endothelial Function, and Clinical Outcome in Patients Presenting With ST‐Segment–Elevation Myocardial Infarction Randomized to Ticagrelor Versus Prasugrel Maintenance Therapy: Long‐Term Follow‐Up of the REDUCE‐MVI Trial

Nina W. van der Hoeven,Gladys N. Janssens,Henk Everaars,Alexander Nap,Jorrit S. Lemkes,Guus A. de Waard,Peter M. van de Ven,Albert C. van Rossum,Javier Escaned,Hernán Mejía-Rentería,Tim ten Cate,Jan J. Piek,Clemens von Birgelen,Marco Valgimigli,Roberto Diletti,Niels P. Riksen,Nicolas M. Van Mieghem,Robin Nijveldt,Maarten A.H. van Leeuwen,Niels van Royen

Platelet Inhibition, Endothelial Function, and Clinical Outcome in Patients Presenting With ST‐Segment–Elevation Myocardial Infarction Randomized to Ticagrelor Versus Prasugrel Maintenance Therapy: Long‐Term Follow‐Up of the REDUCE‐MVI Trial

2020

Background Off‐target properties of ticagrelor might reduce microvascular injury and improve clinical outcome in patients with ST‐segment–elevation myocardial infarction. The REDUCE‐MVI (Evaluation...

Keywords:

Prasugrel
Maintenance therapy
Platelet
Internal medicine
Cardiology
Medicine
Myocardial infarction
Diabetes mellitus
ST segment
Ticagrelor
Clinical trial
Intention-to-treat analysis
reactive hyperemia

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations